Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
10 evidence topics · 8 sources
Phase 3: exclusion of medications that could not be discontinued
Phase 2b: taper and washout of mood and anxiety medications
“The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Before the baseline visit, a medication washout period of 5 half-lives or greater was required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2b: medications tapered at enrollment
“At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants may have tapered multiple medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2b: prohibited substances
“Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monotherapy design and unstudied concomitant use
Psychotherapy: phase 2b rules
“Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants not receiving psychotherapy at screening could not initiate it during the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychotherapy: sponsor treatment paradigm
Concomitant selective serotonin reuptake inhibitor: healthy-participant interaction study
“The present findings suggest that add‐on treatment with LSD to an SSRI is well‐tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No signs of serotonergic toxicity occurred in either study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSRIs did not increase the psychedelic‐induced cardiovascular stimulation or elevation of body temperature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, SSRI therapy has been discontinued before psychedelic administration in clinical Phase II trials, with the exception of one open‐label trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, SSRI discontinuation carries the risk of symptom relapse and withdrawal symptoms, including depressed mood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote